- Home
- MRBK vs PBYI Comparison
MRBK vs PBYI Comparison
Compare MRBK & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRBK
- PBYI
- Stock Information
- Founded
- MRBK 2004
- PBYI 2010
- Country
- MRBK United States
- PBYI United States
- Employees
- MRBK N/A
- PBYI N/A
- Industry
- MRBK Major Banks
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- MRBK Finance
- PBYI Health Care
- Exchange
- MRBK Nasdaq
- PBYI Nasdaq
- Market Cap
- MRBK 177.5M
- PBYI 171.7M
- IPO Year
- MRBK 2017
- PBYI N/A
- Fundamental
- Price
- MRBK $15.16
- PBYI $4.47
- Analyst Decision
- MRBK Buy
- PBYI Strong Buy
- Analyst Count
- MRBK 2
- PBYI 1
- Target Price
- MRBK $17.50
- PBYI $7.00
- AVG Volume (30 Days)
- MRBK 64.7K
- PBYI 679.9K
- Earning Date
- MRBK 10-23-2025
- PBYI 11-06-2025
- Dividend Yield
- MRBK 3.29%
- PBYI N/A
- EPS Growth
- MRBK 69.83
- PBYI 434.29
- EPS
- MRBK 1.61
- PBYI 0.97
- Revenue
- MRBK $106,330,000.00
- PBYI $238,062,000.00
- Revenue This Year
- MRBK $25.14
- PBYI N/A
- Revenue Next Year
- MRBK $8.08
- PBYI N/A
- P/E Ratio
- MRBK $9.46
- PBYI $4.60
- Revenue Growth
- MRBK 17.11
- PBYI 8.63
- 52 Week Low
- MRBK $10.89
- PBYI $2.32
- 52 Week High
- MRBK $17.33
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- MRBK 48.05
- PBYI 45.38
- Support Level
- MRBK $15.35
- PBYI $4.49
- Resistance Level
- MRBK $15.71
- PBYI $5.22
- Average True Range (ATR)
- MRBK 0.20
- PBYI 0.28
- MACD
- MRBK -0.08
- PBYI -0.13
- Stochastic Oscillator
- MRBK 4.51
- PBYI 5.83
About MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.